哈罗制药 HROW
$26.89 +$0.85 (+3.26%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $26.80 -0.33%
开盘$26.40
昨收$26.04
当日区间$25.76 – $26.94
成交量650.9K
市值$1.01B
市盈率（TTM）–
股息率–
财报
财报日平均波动±17.1%近16次财报
收涨次数7 / 1644% 的概率
最佳反应+54.3%
最差反应-36.0%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q2 | 10 Aug 2026 | After Market | ±14.7% | -3.15% | 符合区间 |
| 2026/Q1 | 11 May 2026 | After Market | ±14.1% | -23.69% | 超出定价预期 |
| 2025/Q4 | 2 Mar 2026 | After Market | ±14.5% | -27.96% | 超出定价预期 |
| 2025/Q3 | 10 Nov 2025 | After Market | ±18.7% | +13.47% | 符合区间 |
| 2025/Q2 | 11 Aug 2025 | After Market | ±19.8% | +3.23% | 符合区间 |
| 2025/Q1 | 8 May 2025 | After Market | ±22.7% | +3.43% | 符合区间 |
| 2024/Q3 | 13 Nov 2024 | After Market | ±16.7% | -17.26% | 超出定价预期 |
| 2024/Q2 | 7 Aug 2024 | After Market | ±13.3% | +54.32% | 超出定价预期 |
| 2024/Q1 | 13 May 2024 | After Market | ±18.2% | +34.55% | 超出定价预期 |
| 2023/Q4 | 19 Mar 2024 | After Market | ±21.4% | -1.22% | 符合区间 |
| 2023/Q3 | 13 Nov 2023 | After Market | ±16.0% | -36.01% | 超出定价预期 |
| 2023/Q2 | 9 Aug 2023 | After Market | ±14.8% | -15.45% | 超出定价预期 |
| 2023/Q1 | 11 May 2023 | After Market | ±14.7% | -18.58% | 超出定价预期 |
| 2022/Q4 | 23 Mar 2023 | After Market | ±19.4% | +6.78% | 符合区间 |
| 2022/Q3 | 14 Nov 2022 | After Market | ±21.6% | -4.57% | 符合区间 |
| 2022/Q2 | 9 Aug 2022 | After Market | ±19.8% | +9.91% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
营收构成
2026/Q2 季度
按业务线
基本面
最新报告季度：Q2, ended Jun 2026
营收$70.66M+10.9% YoY
营业利润-$11.01M-196.5% YoY
净利润-$17.27M-445.7% YoY
摊薄每股收益-$0.46-453.8% YoY
自由现金流-$10.29M-838.8% YoY
经营现金流-$9.76M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
毛利率73.3%
营业利润率-1.0%
净利率-13.5%
净资产收益率-114.8%
资产收益率-9.8%
投入资本回报率-7.9%
流动比率2.24
负债/资产比率96.4%
现金及投资$83.89M
总负债$299.80M
净现金（净负债）-$215.91M
暂无评论——快来第一个聊聊 HROW。
登录后参与讨论。